DVAX Share Price

Open 4.80 Change Price %
High 5.00 1 Day -0.15 -3.12
Low 4.60 1 Week -0.05 -1.06
Close 4.65 1 Month -6.65 -58.85
Volume 1910761 1 Year -21.13 -81.96
52 Week High 29.86
52 Week Low 0.00
DVAX Important Levels
Resistance 2 5.02
Resistance 1 4.87
Pivot 4.75
Support 1 4.43
Support 2 4.28
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Dynavax Technologies Corporation (NASDAQ: DVAX)

DVAX Technical Analysis 5
As on 9th Dec 2016 DVAX Share Price closed @ 4.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 15.18 & Strong Sell for SHORT-TERM with Stoploss of 8.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
DVAX Target for December
1st Target up-side 9.17
2nd Target up-side 12.55
3rd Target up-side 15.93
1st Target down-side -0.47
2nd Target down-side -3.85
3rd Target down-side -7.23
DVAX Other Details
Segment EQ
Market Capital 770228480.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.dynavax.com
DVAX Address
DVAX
2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States
Phone: 510-848-5100
Interactive Technical Analysis Chart Dynavax Technologies Corporation ( DVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Dynavax Technologies Corporation
DVAX Business Profile
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company�s pipeline of product candidates includes HEPLISAV, its autoimmune program partnered with GlaxoSmithKline (GSK), its therapy for asthma partnered with AstraZeneca AB (AstraZeneca), and clinical-stage programs for its Universal Flu vaccine and hepatitis B therapy. As of December 31, 2011, its intellectual property portfolio included 18 issued United States patents, claiming compositions and formulations of immunostimulatory sequences (ISS) and Internal Revenue Service (IRS), their methods of use or processes for their manufacture.